Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Anti Pseudomonas aeruginosa IgG1 monoclonal antibody (Primary)
- Indications Pneumonia
- Focus Therapeutic Use
- Sponsors Aridis Pharmaceuticals
- 02 Aug 2017 According to an Aridis Pharmaceuticals media release, first patient has been enrolled.
- 02 May 2017 Status changed from not yet recruiting to recruiting.
- 31 Jan 2017 Status changed from planning to not yet recruiting.